Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Short Communication

Changes in Shear Wave Elastography after Lumacaftor/Ivacaftor Treatment in Children with Cystic Fibrosis

Author(s): Aikaterini Kanavaki, Ino Kanavaki, Pavlos S. Zoumpoulis, Maria Moustaki, Konstantinos Douros* and Ioanna Loukou

Volume 18, Issue 1, 2023

Published on: 24 June, 2022

Page: [93 - 96] Pages: 4

DOI: 10.2174/1574886317666220513105114

Price: $65

Abstract

Background: Lumacaftor/Ivacaftor (LUM/IVA) is an approved combination therapy for cystic fibrosis (CF) patients homozygous for F508del.

Objective: This study aimed to detect changes in liver stiffness measurement (LSM) in patients under this treatment.

Methods: The study population consisted of CF patients homozygous for F508del, 6 to 11 years old, who had been treated for six months with LUM/IVA. Shear wave elastography (SWE) was performed in all of them, before and 6 months after the commencement of treatment.

Results: Thirty-one patients were included in the study. LSM values after treatment were significantly higher than the values before treatment (medians and interquartile ranges of LSM values before and after treatment: 5.6, 5.3-6.3 kPa and, 6.4, 6.0-7.6 kPa, respectively, p<0.001).

Conclusion: SWE can detect early changes in LSM in some CF patients treated with LUM/IVA.

Keywords: Cystic fibrosis, lumacaftor, ivacaftor, shear wave elastography, children, CFLD.

« Previous
[1]
Quinton PM. Cystic fibrosis: Impaired bicarbonate secretion and mucoviscidosis. Lancet 2008; 372(9636): 415-7.
[http://dx.doi.org/10.1016/S0140-6736(08)61162-9] [PMID: 18675692]
[2]
Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease: A clinical and pathologic study. AMA Am J Dis Child 1938; 56(2): 344-99.
[http://dx.doi.org/10.1001/archpedi.1938.01980140114013]
[3]
Kamal N, Surana P, Koh C. Liver disease in patients with cystic fibrosis. Curr Opin Gastroenterol 2018; 34(3): 146-51.
[http://dx.doi.org/10.1097/MOG.0000000000000432] [PMID: 29438119]
[4]
Ling SC, Ye W, Leung DH, et al. Liver ultrasound patterns in children with cystic fibrosis correlate with noninvasive tests of liver disease. J Pediatr Gastroenterol Nutr 2019; 69(3): 351-7.
[http://dx.doi.org/10.1097/MPG.0000000000002413] [PMID: 31436672]
[5]
Sellers ZM, Lee LW, Barth RA, Milla C. New Algorithm for the integration of ultrasound into cystic fibrosis liver disease screening. J Pediatr Gastroenterol Nutr 2019; 69(4): 404-10.
[http://dx.doi.org/10.1097/MPG.0000000000002412] [PMID: 31181020]
[6]
Liguori A, Ainora ME, Riccardi L, et al. The role of elastography in non-alcoholic fatty liver disease. Minerva Gastroenterol 2021; 67(2): 164-70.
[http://dx.doi.org/10.23736/S2724-5985.21.02801-4] [PMID: 34027933]
[7]
Calvopina DA, Noble C, Weis A, et al. Supersonic shear-wave elastography and APRI for the detection and staging of liver disease in pediatric cystic fibrosis. J Cyst Fibros 2020; 19(3): 449-54.
[8]
Gominon AL, Frison E, Hiriart JB, et al. Assessment of liver disease progression in cystic fibrosis using transient elastography. J Pediatr Gastroenterol Nutr 2018; 66(3): 455-60.
[http://dx.doi.org/10.1097/MPG.0000000000001822] [PMID: 29112089]
[9]
Levitte S, Lee LW, Isaacson J, et al. Clinical use of shear-wave elastography for detecting liver fibrosis in children and adolescents with cystic fibrosis. Pediatr Radiol 2021; 51(8): 1369-77.
[http://dx.doi.org/10.1007/s00247-021-05015-w] [PMID: 33759025]
[10]
Ratjen F, Hug C, Marigowda G, et al. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: A randomised, placebo-controlled phase 3 trial. Lancet Respir Med 2017; 5(7): 557-67.
[http://dx.doi.org/10.1016/S2213-2600(17)30215-1] [PMID: 28606620]
[11]
Loukou I, Moustaki M, Plyta M, Douros K. Longitudinal changes in lung function following initiation of lumacaftor/ivacaftor combination. J Cyst Fibros 2020; 19(4): 534-9.
[12]
Debray D, Narkewicz MR, Bodewes FAJA, et al. Cystic fibrosis-related liver disease: Research challenges and future perspectives. J Pediatr Gastroenterol Nutr 2017; 65(4): 443-8.
[http://dx.doi.org/10.1097/MPG.0000000000001676] [PMID: 28753176]
[13]
Behrens CB, Langholz JH, Eiler J, et al. A pilot study of the characterization of hepatic tissue strain in children with Cystic-Fibrosis-Associated Liver Disease (CFLD) by acoustic radiation force impulse imaging. Pediatr Radiol 2013; 43(5): 552-7.
[http://dx.doi.org/10.1007/s00247-012-2560-6] [PMID: 23192669]
[14]
Kutney K, Donnola SB, Flask CA, et al. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. World J Hepatol 2019; 11(12): 761-72.
[http://dx.doi.org/10.4254/wjh.v11.i12.761] [PMID: 31966908]
[15]
Burgel PR, Munck A, Durieu I, et al. Real-life safety and effectiveness of lumacaftor-ivacaftor in patients with cystic fibrosis. Am J Respir Crit Care Med 2020; 201(2): 188-97.
[http://dx.doi.org/10.1164/rccm.201906-1227OC] [PMID: 31601120]
[16]
Sathe MN, Freeman AJ. Gastrointestinal, pancreatic, and hepatobiliary manifestations of cystic fibrosis. Pediatr Clin North Am 2016; 63(4): 679-98.
[http://dx.doi.org/10.1016/j.pcl.2016.04.008] [PMID: 27469182]
[17]
Raizner A, Shillingford N, Mitchell PD, et al. Hepatic inflammation may influence liver stiffness measurements by transient elastography in children and young adults. J Pediatr Gastroenterol Nutr 2017; 64(4): 512-7.
[http://dx.doi.org/10.1097/MPG.0000000000001376] [PMID: 27540711]
[18]
Karlas T, Neuschulz M, Oltmanns A, Wirtz H, Keim V, Wiegand J. ARFI and transient elastography for characterization of cystic fibrosis related liver disease: First longitudinal follow-up data in adult patients. J Cyst Fibros 2013; 12(6): 826-7.

Rights & Permissions Print Cite
Article Metrics
7
© 2024 Bentham Science Publishers | Privacy Policy